Genetic polymorphism associated with non-response to therapy in inflammatory bowel disease patients: a review.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2025-05-01 Epub Date: 2025-08-16 DOI:10.1080/14622416.2025.2547561

Thinagary Jegathesan, Syaratul Dalina Yusoff, Nor Asyikin Mohd Tahir

{"title":"Genetic polymorphism associated with non-response to therapy in inflammatory bowel disease patients: a review.","authors":"Thinagary Jegathesan, Syaratul Dalina Yusoff, Nor Asyikin Mohd Tahir","doi":"10.1080/14622416.2025.2547561","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) poses a major therapeutic challenge due to its chronic course and variable treatment responses. Genetic polymorphisms significantly influence drug efficacy, prompting this review to analyze their role in treatment non-response. A systematic literature search (PubMed/Scopus) using terms like \"genetic polymorphism,\" \"non-response,\" and \"IBD\" identified 25 relevant studies. Key findings linked TNFα (-308 G > A), TNFRSF1A, and TNFRSF1B polymorphisms to reduced anti-TNFα therapy effectiveness. TPMT variants correlated with thiopurine toxicity, while CYP3A4 and CYP3A5 polymorphisms altered tacrolimus metabolism. These genetic markers could serve as predictive tools for personalized IBD treatment, emphasizing the potential of genetic screening in clinical practice. Future research should integrate multi-omics approaches to refine predictive models and advance precision medicine, ultimately improving patient outcomes through tailored therapeutic strategies.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"271-283"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12427478/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14622416.2025.2547561","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Inflammatory bowel disease (IBD) poses a major therapeutic challenge due to its chronic course and variable treatment responses. Genetic polymorphisms significantly influence drug efficacy, prompting this review to analyze their role in treatment non-response. A systematic literature search (PubMed/Scopus) using terms like "genetic polymorphism," "non-response," and "IBD" identified 25 relevant studies. Key findings linked TNFα (-308 G > A), TNFRSF1A, and TNFRSF1B polymorphisms to reduced anti-TNFα therapy effectiveness. TPMT variants correlated with thiopurine toxicity, while CYP3A4 and CYP3A5 polymorphisms altered tacrolimus metabolism. These genetic markers could serve as predictive tools for personalized IBD treatment, emphasizing the potential of genetic screening in clinical practice. Future research should integrate multi-omics approaches to refine predictive models and advance precision medicine, ultimately improving patient outcomes through tailored therapeutic strategies.

查看原文本刊更多论文

与炎症性肠病患者治疗无反应相关的基因多态性：综述

炎症性肠病（IBD）是一个主要的治疗挑战，由于其慢性病程和多变的治疗反应。遗传多态性显著影响药物疗效，促使本综述分析其在治疗无反应中的作用。系统的文献检索（PubMed/Scopus）使用“基因多态性”、“无反应”和“IBD”等术语确定了25项相关研究。关键发现将TNFα (-308 G > A)、TNFRSF1A和TNFRSF1B多态性与降低抗TNFα治疗效果联系起来。TPMT变异与硫嘌呤毒性相关，而CYP3A4和CYP3A5多态性改变了他克莫司的代谢。这些遗传标记可以作为IBD个性化治疗的预测工具，强调了遗传筛查在临床实践中的潜力。未来的研究应该整合多组学方法来完善预测模型和推进精准医学，最终通过量身定制的治疗策略改善患者的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.